TGFB1 and non-small cell lung carcinoma: In non-small cell lung cancer (NSCLC) cells, the pharmacologic inhibition of ERK activation led to more epithelial phenotypes, prevented TGFβ-induced EMT, and increased sensitivity to EGFR inhibition [69].